TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00631202
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients that will satisfy all inclusion/exclusion criteria will be sequentially treated with three single Epoetin alfa administrations. The first time the dose will be 600U/KG BW s.c. in a single administration. The outcome measures will be assessed. A washout period of 1 month will be necessary to eliminate any carry-over effect. A second administration of 1200U/KG BW s.c. will be performed. Outcome measures will be again assessed.
Study: NCT01720407
Drug: Imiquimod cream + surgery
Normalized name: imiquimod Topical Cream
DrugBank: Imiquimod (DB00724)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imiquimod (5 times per week) applied to and extending 1cm beyond the lesion for a period of 4 weeks (i.e. a total of 20 applications), followed by surgery performed four weeks after the last application of the topical treatment. If excision is intralesional, re-excision at 5mm will be performed within a few days (equivalent to 2-stage surgery).
Study: NCT02731950
Drug: Magnesium Sulfate and Bupivacaine 0.125%
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each patient will receive bupivacaine 0.125% with 5% magnesium sulphate by infusion through a catheter used for epidural analgesia, positioned presternal.
Study: NCT02144194
Drug: Vinorelbine-Docetaxel
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vinorelbine I.V: 20mg/m2 D1 Docetaxel: 60mg/m2 D1 Vinorelbine Oral: 60mg/m2 D8 Every 3 weeks x 6 cycles
Study: NCT02144194
Drug: Vinorelbine
Normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Vinorelbine 60mg/m2 or 80mg/m2 D1, D8 every 3 weeks until disease progression, unacceptable toxicities or patient refusal to continue (dose schedule is at investigator's discretion)
Study: NCT04321096
Drug: Camostat Mesilate
Normalized name: Camostat mesilate
DrugBank: Camostat (DB13729)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serine protease inhibitor that blocks TMPRSS-2 mediated cell entry of SARS-CoV-2
Study: NCT00970268
Drug: Aclidinium bromide
Normalized name: Aclidinium Bromide
DrugBank: Clidinium (DB00771)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Aclidinium bromide 200 μg, oral inhalation twice per day for 52 weeks of treatment
Study: NCT00970268
Drug: Aclidinium bromide
Normalized name: Aclidinium Bromide
DrugBank: Clidinium (DB00771)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Aclidinium bromide 400 μg, oral inhalation twice per day for 52 weeks of treatment
Study: NCT03736265
Drug: Carvedilol
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carvedilol is started at a dose of 6.25 mg once daily. After 1 week, this will increased to a dose of 12.5 mg once daily. Target dose of 12.5 mg once daily will be maintained if systolic blood pressure does not fall below 90 mm Hg and HR 50 beats per minute.
Study: NCT01655199
Drug: Combination ipratropium/salbutamol or placebo (nebulization)
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For the visit 2, COPD patients will be randomly assigned a combination of ipratropium/salbutamol or a placebo in a double-blind crossover design. For the visit 3, the other intervention drug will be assigned. The bronchodilation obtained with the medication will allow to determine if the 3-min step test is sensitive by detecting an improvement of exertional dyspnea following bronchodilation.
Study: NCT02324738
Drug: Mefloquine and Dihydroartemisinin-piperaquine
Normalized name: .alpha.-dihydroartemisinin
DrugBank: Mefloquine (DB00358)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 tablets of mefloquine and 3 tablets of dihydroartemisinin-piperaquine single dose
Study: NCT02324738
Drug: Mefloquine
Normalized name: Mefloquine
DrugBank: Mefloquine (DB00358)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 tablets of Mefloquine single dose
Study: NCT01861509
Drug: BP-C1
Normalized name: C1-INH
DrugBank: Human C1-esterase inhibitor (DB06404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BP-C1, 0.05% solution for injection; doses: 0.035 mg/kg body weight (0.07 mL/kg) intramuscularly once daily for 32 consecutive days
Study: NCT04554615
Drug: Insulin
Normalized name: Insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: insulin infusion to control postoperative hyperglycemia
Study: NCT00321815
Drug: PF-3512676 + Erlotinib
Normalized name: PF-3512676 free acid
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PF-3512676 0.2 mg/kg subcutaneously on days 1, 8 and 15 of each 21 day cycle until disease progression or unacceptable toxicity.~Erlotinib 150 mg orally daily (21 day cycles) until disease progression or unacceptable toxicity
Study: NCT00321815
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erlotinib 150 mg orally daily (21 day cycles) until disease progression or unacceptable toxicity
Study: NCT00487253
Drug: Miltefosine
Normalized name: Miltefosine
DrugBank: Miltefosine (DB09031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Miltefosine, dosage 1,5mg -2,5mg/kg/day, during 28 days.
Study: NCT00487253
Drug: Meglumine antimoniate
Normalized name: meglumine antimoniate
DrugBank: Meglumine antimoniate (DB13732)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral meglumine antimoniate Amp of 5ml (83mg/ml). Dosage: 20mg/kg/day one doses IM, during 20 days.
Study: NCT00019344
Drug: alvocidib
Normalized name: Alvocidib
DrugBank: Alvocidib (DB03496)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00555620
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin is given 110mg/m\^2 through a vein on day 1 every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
Study: NCT00555620
Drug: sunitinib malate
Normalized name: Sunitinib Malate
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: sunitinib is given orally 25mg/day for 14 days followed by 7 days of drug free period.
Study: NCT00555620
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin is given 80mg/m\^2 through a vein on day 1 every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
Study: NCT03696342
Drug: Pazufloxacin
Normalized name: pazufloxacin
DrugBank: Pazufloxacin (DB11774)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazufloxacin 0.6%. by Sophia Laboratories, topical ophthalmic~1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days.
Study: NCT03696342
Drug: Zymar
Normalized name: Zymar
DrugBank: Gatifloxacin (DB01044)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gatifloxacin 0.3%. by Allergan, topical ophthalmic~1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days.
Study: NCT04052880
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: In Cycles 1 through 12, lenalidomide will be self-administered at a dose of 15 mg orally each day on Days 1 through 21 of each 28-day cycle.~For subjects with CrCl 30-60mL/min, lenalidomide will be reduced to 10mg daily, and for subjects with CrCl 15-30 mL/min, lenalidomide will be reduced to 5mg daily.~In maintenance phase: lenalidomide will be administered at one dose level below Cycles 1-12 dosing ie 10 mg orally daily.~In maintenance, for subjects with CrCl 30-60 mL/min, lenalidomide will be reduced to 5 mg daily during maintenance treatment, and for subjects with CrCl 15-30 mL/min, lenalidomide will be reduced to 5 mg every other day during maintenance treatment.
Study: NCT04052880
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone will be self-administered orally at a total dose of 20 mg weekly during cycles.~However, the dexamethasone 20 mg oral or IV (only if oral is not available) dose administered as a preinfusion medication on daratumumab infusion days replaces the oral dexamethasone dose for that day. Dexamethasone will be administered until the subject experiences disease progression or unacceptable toxicity.~In the maintenance phase, dexamethasone/steroid premedications may be tapered or discontinued in the absence of daratumumab related infusion reactions/based on patient tolerance. In the event of persistent daratumumab related infusion reactions, the least amount of steroid premedications needed to prevent the same may be used.
Study: NCT00244426
Drug: indobufen
Normalized name: indobufen
DrugBank: Indobufen (DB12545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indobufen capsules 100 and 200mg
Study: NCT00244426
Drug: aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid capsules 300mg
Study: NCT02187120
Drug: Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid is a synthetic lysine derivative that inhibits fibrinolysis by blocking the lysine binding sites on plasminogen therefore inhibiting the conversion of plasminogen to plasmin. Intravenous injection of 1g Tranexamic Acid will be administered in the pre-hospital setting followed by 1g Tranexamic Acid infused intravenously over 8 hours initiated in the hospital emergency department.
Study: NCT02632630
Drug: Amino Acids w/Electrolytes in Dextrose
DrugBank: Amino acids (DB09393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive peripheral parenteral nutrition to a maximum of 2L/day (with a minimum rate of 45mL/hour and a maximum rate of 85mL/hour) of pre-packaged Peri-OLIMEL 2.5% E. The PPN will be administered in place of their maintenance crystalloid solution, and will be adjusted or stopped as clinically indicated by the attending medical team., for up to 5 days of hospitalization or until discharge, whichever is sooner.
Study: NCT02632630
Drug: Crystalloid solutions
Normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care intravenous maintenance fluid administration for up to 5 days of hospitalization or until discharge, whichever is sooner.
Study: NCT00965393
Drug: bradykinin receptor antagonist (HOE-140)
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Bradykinin (DB12126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic infusion of bradykinin receptor antagonist (HOE-140)
Study: NCT01345253
Drug: Belimumab
Normalized name: Belimumab
DrugBank: Belimumab (DB08879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10mg/kg administered intravenously. Dosing at Weeks 0, 2, and 4, then every 4 weeks through Week 48, with a final evaluation at Week 52. All study subjects will receive standard SLE therapies during the study.
Study: NCT01072058
Drug: TNF blockers (infliximab, adalimumab, etanercept)
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects enrolled, who were eligible to anti-TNF therapy, were evaluated by echocardiography (conventional and tissue doppler imaging)and biomarkers (NT-proBNP and troponin T)at baseline. Then, they were treated with adalimumab 40mg subcutaneously every 2 weeks or infliximab 3 or 5mg/Kg (0, 2 and 6 weeks and thereafter every 8 weeks)or etanercept 50mg subcutaneously every week. And they were re-evaluated with 6, 12, 18 and 24 months from first dose of the TNF blocker .
Study: NCT01816165
Drug: Acipimox
Normalized name: acipimox
DrugBank: Acipimox (DB09055)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will take acipimox 250mg by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day.
Study: NCT01560962
Drug: povidone iodine
Normalized name: POVIDONE IODINE
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: over the counter (OTC) 5% povidone iodine (PI)
Study: NCT03946345
Drug: Iohexol Inj 300 MG/ML
DrugBank: Iohexol (DB01362)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Administration of iohexol: each 24 hours one bolus IV (1-5ml) during 72 hours~* Blood samples are drawn for analysis of iohexol concentrations and other parameters of renal function at 2, 5 and 7 hours after administration~* Urine is collected from catheter between 4 and 6 hours after adminstration to determine urine creatinine and iohexol concentrations
Study: NCT01167816
Drug: Vidaza
Normalized name: Vidaza
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Vidaza will be administered subq daily for 5 consecutive days each 28-day cycle
Study: NCT01835847
Drug: Tipepidine Hibenzate
Normalized name: trimethylpentanediyl dibenzoate
DrugBank: Tipepidine (DB13474)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01123356
Drug: Ofatumumab
Normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: * Ofatumumab 2000 mg (300 mg on first cycle) IV on day 1 for up to 6 cycles (28 day cycles)~* Treatment to be administered for up to 6 cycles
Study: NCT01123356
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: -Lenalidomide 10 mg (5 mg on first cycle) PO days 8-28 for up to 6 cycles (28 day cycles)
Study: NCT01573741
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: a single infusion of ketamine hydrochloride (0.5 mg/kg) infused over 40 minutes
Study: NCT00553800
Drug: bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00553800
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01693393
Drug: Cyclosporine A
Normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive Cyclosporine A in a dose of ca. 2mg/kg/BW daily for a 16 week period
Study: NCT04362722
Drug: L19IL2 +L19TNF
Normalized name: L19IL2
DrugBank: Darleukin (DB17157)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single or multiple intratumoral administration of a mixture of L19IL2 and L19TNF will be performed once weekly for up to 4 weeks into all injectable lesions present at the beginning of treatment or appearing during treatment phase The dose will be constituted by 6.5 Mio IU L19IL2 (\~1.08 mg) and 200 µg L19TNF.
Study: NCT02275806
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02275806
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02331771
Drug: Donepezil
Normalized name: Donepezil
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Donepezil 5 mg once daily 2 days before ECT and continuing through the last ECT procedure.
Study: NCT03792945
Drug: local injection
Normalized name: Sclerosing agents for local injection
DrugBank: Elocalcitol (DB06194)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In addition to the local injection, carpal tunnel brace will be given.
Study: NCT00003376
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003376
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003376
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00003376
Drug: vinblastine
Normalized name: Vinblastine
DrugBank: Vinblastine (DB00570)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00110422
Drug: Irbesartan
Normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets, Oral, 150 mg. titrated to 300 mg, once daily, 28 weeks.
Study: NCT00110422
Drug: Hydrochlorothiazide
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets, Oral, 12.5 mg. titrated to 25 mg, once daily, 28 weeks.
Study: NCT00447499
Drug: Somatuline Autogel (lanreotide acetate)
Normalized name: Somatuline
DrugBank: Lanreotide (DB06791)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Injections
Study: NCT04052880
Drug: Ixazomib
Normalized name: Ixazomib
DrugBank: Ixazomib (DB09570)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: During maintenance treatment, if choice of maintenance therapy includes ixazomib, ixazomib will be administered at 3 mg orally daily on Days 1,8, and 15 of each cycle. For subjects with CrCl 15-30 mL/min, ixazomib will be reduced to 2.3 mg once per week during maintenance treatment.
Study: NCT01684345
Drug: Dose 1 gevokizumab
Normalized name: Gevokizumab
DrugBank: Gevokizumab (DB12119)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for subcutaneous injection
Study: NCT01684345
Drug: Dose 2 gevokizumab
Normalized name: Gevokizumab
DrugBank: Gevokizumab (DB12119)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for subcutaneous injection
Study: NCT00648271
Drug: Metoprolol Tartrate Tablets 25 mg
Normalized name: Metoprolol Tartrate
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2x50mg, single dose fed
Study: NCT01190436
Drug: Bisoprolol
Normalized name: Bisoprolol
DrugBank: Bisoprolol (DB00612)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bisoprolol will be administered at an initial dose of 5 milligram (mg) once daily for 2 weeks. If the blood pressure would be greater than or equal to 130/80 mmHg after 2 weeks, then dose will be adjusted to 10 mg once daily. Total duration of study treatment will be 12 weeks.
Study: NCT04063449
Drug: endostar/PD-1 inhibitor
DrugBank: Endostar (DB11727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiangiogenic therapy plus immunotherapy and chemotherapy
Study: NCT04063449
Drug: endostar
Normalized name: Endostar
DrugBank: Endostar (DB11727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiangiogenic therapy plus chemotherapy
Study: NCT03451903
Drug: Actilyse
Normalized name: Actidose
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Actilyse is the intra-venous agent used for intra-venous thrombolysis in the acute phase of cerebral infarction.
Study: NCT02107235
Drug: oral rigosertib
Normalized name: Rigosertib
DrugBank: Rigosertib (DB12146)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02107235
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00083148
Drug: irinotecan hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01605084
Drug: Atazanavir
Normalized name: Atazanavir
DrugBank: Atazanavir (DB01072)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Capsule, Oral, 300 mg, Once daily (QD), 48 weeks
Study: NCT01605084
Drug: Darunavir
Normalized name: Darunavir
DrugBank: Darunavir (DB01264)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral, Two 400 mg Tablets, Once daily (QD), 48 weeks
Study: NCT01605084
Drug: Ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablet, Oral, 100 mg, Once daily (QD), 48 weeks
Study: NCT00275418
Drug: beta carotene from Dunaliella algae
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02199444
Drug: Sevelamer
Normalized name: Sevelamer
DrugBank: Sevelamer (DB00658)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The dose of Sev was 2400 mg (800 mg three times a day) in all patients.
Study: NCT01493388
Drug: insulin
Normalized name: Insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be treated according to routine clinical practice at the discretion of the treating physician.
Study: NCT02301078
Drug: Collagenase clostridium histolyticum
Normalized name: Collagenase Clostridium Histolyticum
DrugBank: Collagenase clostridium histolyticum (DB00048)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xiaflex injection into palpable cords (day 0), physical manipulation (day 7)
Study: NCT00402298
Drug: MDMA
Normalized name: MDMA
DrugBank: Midomafetamine (DB01454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive an initial dose of 125 mg MDMA orally followed 2.5 hours later by 62.5 mg MDMA orally during the course of a day-long therapy session.
Study: NCT00402298
Drug: MDMA
Normalized name: MDMA
DrugBank: Midomafetamine (DB01454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive an initial dose of 25 mg MDMA orally followed 2.5 hours alter by a supplemental dose of 12.5 mg MDMA orally during the course of each of two day-long therapy sessions.
Study: NCT03045029
Drug: Oral treprostinil
Normalized name: Treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sustained-release oral tablets for TID administration
Study: NCT00472082
Drug: efalizumab
Normalized name: Efalizumab
DrugBank: Efalizumab (DB00095)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administration of a test dose of efalizumab 0.7mg/kg will be administered at enrollment. Weekly subcutaneous injections of efalizumab 1mg/kg will begin with study visit 2 and continue for 1 year for this pilot study.
Study: NCT00420498
Drug: Atomoxetine (Strattera™)
Normalized name: atomoxetine Oral Capsule [Strattera]
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02069379
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Women classified as insulin resistant will participate in both a placebo and a metformin treatment arm, each lasting about 16 weeks. Women will be randomized to order of treatment arms.
Study: NCT04113187
Drug: Propranolol treatment
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg twice a day (morning and evening), per os, during three months
Study: NCT03469089
Drug: Ketamine 0.58
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketamine (0.23 mg/kg bolus + 0.58 mg/kg/h)
Study: NCT03469089
Drug: Ketamine 0.31
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketamine (0.12 mg/kg bolus + 0.31 mg/kg/h)
Study: NCT03469089
Drug: Modafinil
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Modafinil tablet 100 mg placed in a capsule
Study: NCT03469089
Drug: Placebo for ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.9 % NaCl infusion solution
Study: NCT03469089
Drug: Placebo for modafinil
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Placebo capsule for modafinil capsule
Study: NCT00014508
Drug: cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00014508
Drug: fludarabine phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no